Search results
FDA Approves First-Ever RSV Vaccine for Adults 60 and Older
Health via Yahoo News· 1 year agoThe FDA approved Arexvy, the world’s first vaccine for RSV, on Wednesday. Manufactured by...
FTSE 100: GSK tops forecasts after strong sales of shingles vaccine
Yahoo Finance UK· 1 year agoGSK (GlaxoSmithKline) logo is seen in this illustration, August 10, 2022. REUTERS/Dado...
First-ever vaccine to prevent RSV in older adults wins FDA approval
The Hill via Yahoo News· 1 year agoFederal regulators gave the green light to the first-ever vaccine to prevent the respiratory disease...
2 Dividend Stocks to Double Up On Right Now
Motley Fool· 2 years agoAbbVie (NYSE: ABBV) and GlaxoSmithKline (NYSE: GSK) have much in common. They are huge pharmaceutical companies that have a long record of success,...
Why It Took So Long to Finally Get an RSV Vaccine
Time via Yahoo News· 1 year agoCredit - Getty Images; GSK Respiratory syncytial virus (RSV) can dangerously compromise breathing, especially for infants and the elderly. But there has...
GSK's India unit posts Q2 profit rise on strong vaccine demand
Reuters via Yahoo Finance· 7 months agoBENGALURU (Reuters) - GlaxoSmithKline Pharmaceuticals reported a 12.5% rise in quarterly profit on...
Shingles vaccine guides GSK to higher sales and profits
Press Association News via AOL· 1 year agoGlaxoSmithKline (GSK) has delivered higher profits and revenues after it was buoyed by bumper sales...
The race to an RSV vaccine could soon be over, decades after the first attempt
NBC Universal via AOL· 1 year agoNo RSV vaccine has ever been approved in the US. Decades after the first attempt to develop an RSV...
FDA approves 1st RSV vaccine
Live Science via Yahoo News· 1 year agoan older woman with white hair sits in a doctor's office with her sleeve rolled up to show a bandage on her arm, as if she'd received a vaccine. She and...
GSK India arm's Q3 profit falls on government price cap
Reuters via Yahoo Finance· 4 months agoGlaxoSmithKline Pharmaceuticals, the Indian unit of the UK's GSK, reported a 3% fall in...